Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin and Osimertinib in Transformed SCLC
NCT07153055Phase 2Recruiting
- Start
- Jan 2027
- Primary completion
- Apr 2029
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in small cell lung cancer (SCLC). Planned start Jan 2027; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07153055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07153055.